Mustang Bio is a clinical-stage biopharmaceutical company founded in 2015 and based in the United States. The company is dedicated to acquiring, developing, and commercializing innovative cancer immunotherapy products designed to harness the patient's immune system to target and destroy cancer cells. Their current development focuses include CD123, CD20, and CS1.
The company recently received a $2.50M Post-IPO Equity investment on 20 June 2024.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $2.50M | - | 20 Jun 2024 | |
| Post-IPO Equity | $4.00M | - | 29 Apr 2024 | |
| Post-IPO Equity | $4.40M | - | 26 Oct 2023 | |
| Post-IPO Debt | $75.00M | 1 |
|
08 Mar 2022 |
| Grant | $2.00M | 1 | National Institutes of Health | 01 Nov 2021 |
No recent news or press coverage available for Mustang Bio.
We care about your data, and we'd love to use cookies make your experience better.
